<DOC>
	<DOCNO>NCT00803309</DOCNO>
	<brief_summary>In study intend treat patient chronic hepatitis C genotype 2 3 characteristic associated poor treatment response additional 12 24 week beyond standard treatment PEG-IFN alpha-2b plus ribavirin . The objective study compare efficacy treatment extension 12 versus 24 week patient HCV-genotypes 2 3 treat 1.5 µg/kg PEG-IFN alpha-2b 800-1400 mg ribavirin ( standard dose ) 24 week ( standard duration ) HCV-RNA negative ( &lt; 15 IU/ml ) 4 week standard treatment HCV-RNA negative 16-24 week standard treatment .</brief_summary>
	<brief_title>Study Assess Efficacy 12 Versus 24 Weeks Extended Treatment HCV-Genotype 2/3 Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Male female patient HCVgenotype 2/3 chronic hepatitis C document detectable plasma HCV RNA ( &gt; 15 IU/mL ) positivity antiHCV antibody Age ≥ 18 year Compensated liver disease ( ChildPugh Grade A clinical classification ) Negative urine blood pregnancy test ( one ; woman childbearing potential ) document within 24hour period prior first dose study drug . Additionally , fertile male female must use two form effective contraception treatment 7 month treatment end . This include use birth control pill ( interaction investigational drug ) , IUDs , condom , diaphragm , implant , surgically sterilize , postmenopausal state . At least one contraception method must barrier method Ongoing treatment 1.5 µg/kg PegInterferon alpha2b ( PegIntron® ) &gt; 10.6 mg/kg ribavirin ( Rebetol® ) No rapid virological response ( HCVRNA positive week 4 ongoing therapy ) Willingness give write informed consent willingness participate comply study protocol Women ongoing pregnancy breast feed Male partner woman pregnant Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , HBeAg , antiHIV , HIVRNA History evidence medical condition associate chronic liver disease HCV associate ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) History evidence bleed esophageal varix condition consistent decompensated liver disease Patients liver cirrhosis lesion suspicious hepatic malignancy screen Absolute neutrophil count ( ANC ) &lt; 750 cells/mm3 screen Platelet count &lt; 50,000 cells/mm3 screen Hb &lt; 10 g/dl screen Dose modification PegInterferon alpha2b ( PegIntron® ) ribavirin ( Rebetol® ) first 4 week ongoing therapy Interferon alpha ribavirin therapy time point actual ongoing treatment Less 80 % adherence treatment ongoing treatment randomization ( week 2022 ongoing treatment ) Serum creatinine level &gt; 1.5 time upper limit normal screen History severe psychiatric disease , especially depression ( ICD 10 code F30F33 ) . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time . Patients exclude history suicidal attempt evident . If hospitalization psychiatric disease , period disability due psychiatric disease document , psychiatric consultation mandatory . Patients mild moderate psychiatric disease ( ICD 10 code F32.0 , F32.1 , F33.0 , F33.1 ) allow included trial regular monitoring psychiatrist perform trial History severe seizure disorder current anticonvulsant use History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis ) History evidence autoimmune disease History evidence chronic pulmonary disease associate functional limitation History significant cardiac disease could worsen acute anemia ( e.g . NYHA Functional Class III IV , myocardial infarction within 6 month prior treatment PegInterferon/ribavirin therapy , ventricular tachyarrhythmias require ongoing treatment , unstable angina ) Evidence thyroid disease poorly control prescribed medication Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration ) History major organ transplantation exist functional graft History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) 6 month prior first dose study drug expectation treatment need time study Patients evidence tuberculosis Drug abuse within 6 month prior first dose study drug excessive alcohol consumption . Patients methadone/polamidone/buprenorphine program exclude Any investigational drug and/or participation another clinical study prior 6 month actual ongoing antiviral treatment Limited contractual capability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic HCV-genotype 2/3</keyword>
	<keyword>Efficacy treatment extension</keyword>
	<keyword>PegIntron</keyword>
	<keyword>pegylated interferon alpha-2b</keyword>
	<keyword>Rebetol</keyword>
	<keyword>ribavirin</keyword>
</DOC>